This study evaluated breast cancer cryoablation without surgical excision in patients who were ineligible for clinical trials due to unfavorable characteristics. Involving 112 women, the study found a low incidence of minor adverse events (6.3%) and high technical success (98.2%). Over a median follow-up of 2 years, 10.9% experienced ipsilateral breast tumor recurrence (IBTR). The cumulative incidence of IBTR was 5.3% at 1 year, 12.2% at 2 years, and 18.2% at 3 years. The findings suggest that cryoablation is a safe and effective alternative to surgery for select patients with challenging conditions.
3